ERBB2 and triple-negative breast carcinoma: Nowadays, efforts are focused largely on understanding triple-negative breast cancer (TNBC) biology, since it is the most clinically aggressive group as (i) there is no expression of three biomarkers (ER, PR and Her2), (ii) it affects the youngest women, and (iii) current treatment of TNBC relies largely on chemotherapy and radiotherapy [17,20].